Healthcare Industry News: Mobetron
News Release - October 29, 2007
St. Joseph Hospital Selects IntraOp Medical's Mobetron to Deliver Advanced Cancer TreatmentKey Mobetron benefits include increased survival rates, better local tumor controls, shorter treatment cycles and fewer side effects
SUNNYVALE, Calif.--(HSMN NewsFeed)--IntraOp Medical Corporation (OTCBB: IOPM ), a provider of innovative technology solutions for the treatment and eradication of cancer, announced today that St. Joseph Hospital in Orange, CA has selected its Mobetron® device. Mobetron directly delivers intraoperative electron radiation therapy (“IOERT”) to patients as they undergo surgery in a highly safe and efficient manner.
St. Joseph Hospital is one of 14 hospitals in the St. Joseph Health System, with facilities located throughout California and Texas. The St. Joseph Hospital Cancer Center, established in 1987, is the only center in Orange County to provide comprehensive cancer care, including a full range of diagnostic services, chemotherapy, radiation therapy, surgery, clinical trials, and stem cell transplants.
Recently, the center became one of 16 hospitals named by the National Cancer Institute (NCI) to participate in a three-year pilot for the NCI Community Cancer Centers Program (NCCCP), to deliver the most advanced cancer care to a greater number of Americans in the communities in which they live. St. Joseph Hospital was the only hospital on the West Coast named for the NCCCP pilot. The hospital currently treats more than 1,500 new cancer patients each year.
Mobetron will be used at St. Joseph Hospital to safely and efficiently treat a wide variety of cancers, including breast, colorectal, head and neck, and abdominal cancers. With Mobetron, radiation and surgical oncologists can pinpoint the exact area that requires radiation and immediately deliver high doses directly to the affected tissue during cancer surgery. Hospitals can wheel Mobetron between existing operating rooms without investing in costly renovations to accommodate traditional radiation therapy devices. Key patient benefits of this early and powerful start to radiation therapy include: better local tumor control, increased survival rates, shorter treatment cycles and fewer side effects.
“We are pleased to be able to offer Mobetron as an integral part of our cancer treatment program,” said Dr. Robert Ash, Radiation Oncologist at St. Joseph Hospital. “The acquisition of this important cancer-fighting device strengthens our efforts to be a world-class treatment facility and supports the hospital’s mission to continue to improve the health and quality of life of the people in the communities we serve.”
John Powers, CEO of IntraOp Medical said, “Mobetron is fundamentally changing the way cancer patients are being treated today and positively impacting their survival. We look forward to working closely with St. Joseph Hospital to provide the most advanced medical technology available to effectively and efficiently treat cancer. The hospital’s decision to use Mobetron demonstrates St. Joseph’s commitment to provide the very best medical care to its patients.”
Other U.S. institutions currently using Mobetron include: Clarion Methodist Hospital Indianapolis, Mayo Clinic Phoenix, Ohio State University, St. Vincent Indianapolis Hospital, University Hospital Cleveland, University of California San Francisco, University of Louisville and University of North Carolina.
For more information on St. Joseph Hospital, please visit: www.sjo.org.
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
Source: IntraOp Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.